BIONTECH

Uğur Şahin and Özlem Türeci are both children of Turkish immigrants who moved to Germany for work. They met during medical training, fell in love over shared obsessions about cancer immunology, and reportedly worked in the lab on their wedding day.

That detail is not a PR myth — it tells you everything about who these people are.

They founded BioNTech in 2008 in Mainz with Christoph Huber, a fellow cancer researcher, and a mandate from early backer and billionaire Thomas and Andreas Strüngmann. The mission was singular: use mRNA technology to train the immune system to fight cancer.

Not vaccines. Not infectious disease.

Cancer.

For over a decade they worked in relative obscurity. They raised money, ran trials, built a pipeline of individualized cancer therapies, and got almost no mainstream attention.

The scientific community knew who they were. The world did not.

Then January 2020 happened. Şahin read a paper about a mysterious respiratory illness spreading in Wuhan and immediately told his team the world was about to change.

Within days he had emailed Pfizer. Within weeks they had a partnership.

Within eleven months they had a vaccine authorized for emergency use. The speed was so extraordinary that some people didn't believe it — which became its own problem.

But the science was real, and it had been in development for fifteen years.

BioNTech's core technology is mRNA — messenger RNA. The basic idea: instead of injecting a weakened or dead pathogen into the body, you inject genetic instructions that tell your own cells to produce a piece of the pathogen.

Your immune system sees it, learns to recognize it, and builds a defense. Then the mRNA degrades and disappears.

No virus entered your body. Just a recipe.

The COVID-19 vaccine was BioNTech's first commercial product and it was licensed jointly with Pfizer, who handled manufacturing scale and distribution. BioNTech received roughly half the profits.

That deal structure meant Pfizer's massive commercial infrastructure did the heavy lifting while BioNTech kept enormous economic upside.

The actual business model is pharmaceutical: develop proprietary therapies, run clinical trials, seek regulatory approval, license or co-commercialize. The revenue model is milestone payments, royalties, and direct sales.

The COVID vaccine alone generated over $21 billion in revenue in 2021 and $17 billion in 2022 before demand normalized.

Longer term, BioNTech is betting that the same mRNA platform can be used to create individualized cancer vaccines — therapies tailored to a specific patient's tumor mutations. Each therapy is essentially custom-made.

It's the hardest and most expensive kind of medicine to develop, and also potentially the most transformative.

The COVID-19 mRNA vaccine (Comirnaty, co-developed and co-marketed with Pfizer) is the product that put BioNTech on the map. It uses mRNA encoding the SARS-CoV-2 spike protein to prime the immune system.

It was the first mRNA vaccine ever authorized for human use, anywhere in the world. About 3 billion doses were administered globally.

Beyond COVID, BioNTech's pipeline includes individualized neoantigen-specific immunotherapy — basically custom cancer vaccines built around each patient's specific tumor mutations. Their most advanced cancer candidate, BNT111, targets melanoma.

BNT122 (developed in partnership with Genentech/Roche) is a personalized cancer vaccine that generated strong early data in colorectal cancer trials.

They're also developing mRNA-based flu vaccines and combination COVID/flu vaccines, aiming to translate the technology platform into a broader respiratory infectious disease business. The flu vaccine market alone is enormous, and mRNA could theoretically produce faster, more effective flu vaccines than the egg-based production methods the industry has used for decades.

Think of BioNTech less as a company with one product and more as a platform company. The mRNA technology is the core asset.

Everything else — COVID, cancer, flu, HIV, tuberculosis — is an application layer built on top of it.

BioNTech didn't grow the way most startups do. There was no viral loop, no growth hack, no product-market fit epiphany in a coffee shop.

They grew through patient capital, deep science, and one massive, once-in-a-generation pivot.

The pivot was the whole game. When Şahin recognized COVID-19 as a pandemic threat in January 2020, BioNTech had a mature mRNA platform but no commercial product.

He calculated that adapting their technology to a coronavirus target was feasible in weeks. He reached out to Pfizer — a company with manufacturing facilities, regulatory relationships, and a global distribution network that BioNTech simply couldn't replicate.

Pfizer said yes fast.

The counterintuitive move: they ran vaccine development and manufacturing scale-up simultaneously. Normal drug development is sequential — you develop, then you scale.

BioNTech and Pfizer bet billions on manufacturing capacity before they knew if the vaccine worked. If the trials had failed, that was an enormous write-off.

They didn't fail.

The Pfizer partnership was also strategic self-preservation. BioNTech didn't have the balance sheet to fund a global vaccine rollout alone.

Pfizer's name on the label gave regulators and governments confidence. The partnership traded full control for global reach — and it paid off at a scale BioNTech could never have achieved independently.

The post-COVID hangover is the most pressing challenge BioNTech faces right now. COVID vaccine demand has cratered.

Revenue went from $21.6 billion in 2021 to roughly $3.8 billion in 2023. They went from printing money to burning it again in the span of eighteen months.

The core scientific bet — individualized mRNA cancer vaccines — is still unproven at scale. These therapies require sequencing a patient's tumor, identifying mutation targets, designing a custom mRNA sequence, manufacturing it, and administering it — all for one person.

The logistics and cost are staggering. Early trial results with Moderna (their main mRNA competitor) and Merck's cancer vaccine work are promising, but 'promising' in oncology trials has broken hearts before.

There's also a reputational overhang from vaccine skepticism. The speed of the COVID vaccine rollout — which was a genuine scientific achievement — became a source of distrust for a significant portion of the global population.

BioNTech's future products will face that headwind regardless of how good the science is.

And underneath all of it: BioNTech is now a large company with expensive infrastructure, a growing pipeline of candidates, and no guaranteed next blockbuster. They need one of their cancer programs to work.

They need it badly.

BioNTech's foundational capital came from Andreas and Thomas Strüngmann, the German billionaire twins who sold their generic pharma company Hexal to Novartis for around $7.5 billion in 2005. They backed BioNTech from early on with the kind of patient, long-horizon money that early-stage biotech requires.

Without that anchor capital, BioNTech likely would have needed to sell itself or abandon the mission years before the pandemic.

In 2018, Pfizer made a $135 million equity investment in BioNTech as part of their initial influenza vaccine collaboration. That relationship predated COVID and meant the two companies already had operational chemistry when Şahin reached out in early 2020.

BioNTech went public on the NASDAQ in October 2019, raising $150 million at a $3.4 billion valuation — modest by later standards. The IPO gave them a public currency and balance sheet flexibility right before the pandemic hit.

In April 2020, the German government invested €300 million through KfW Development Bank as part of a broader effort to support German vaccine development. Having government backing also gave BioNTech credibility and regulatory facilitation that purely private companies don't get.

Fidelity Management, Redmile Group, and various institutional investors filled out later rounds. By 2021, the Strüngmann family's stake alone was worth tens of billions.